CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 25 enrolled / 25 target
Drug / intervention
Belantamab mafodotin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07217119
NCT07217119Phase 1ActiveUpdate Overdue (0.3/mo)Completion was 14mo ago
CompareCT.gov

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination

GlaxoSmithKline·interventional·Posted Oct 15, 2025·Updated Jun 25, 2026

In Brief

A Phase 1 clinical trial evaluating Belantamab mafodotin and Feladilimab for Multiple Myeloma. Active but no longer recruiting, targeting 25 participants across 11 sites in 8 countries.

Signals

Enrollment appears stalled

Detailed Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, France, Germany, Netherlands, Spain, Sweden, United States
Collaborators--

Timeline

Phase 1Active
20202021202220232024202520262027
First PostedOct 15, 2025
Enrollment StartNov 26, 2019
Primary CompletionApr 17, 2025
Study CompletionMar 11, 2027
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 9 months ago

Arms & Interventions

Belantamab mafodotin + Feladilimabexperimental

Drug: Belantamab mafodotinDrug: Feladilimab

Interventions

Belantamab mafodotindrug

Belantamab mafodotin will be administered.

Feladilimabdrug

Feladilimab will be administered.